JPRN-UMIN000009110
Recruiting
Phase 2
A observational study for safety and efficacy of Fulvestrant 500mg in postmenopausal patients with ER positive advanced or recurrent breast cancer after prior endocrine treatment. (SBCCSG-29) - SBCCSG-29:Fulvestrant observational study
Saitama Breast Cancer Clinical Study Group(SBCCSG)0 sites100 target enrollmentOctober 15, 2012
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- ocally advanced or metastatic breast cancer
- Sponsor
- Saitama Breast Cancer Clinical Study Group(SBCCSG)
- Enrollment
- 100
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\.Current or prior double cancer within 5 years. 2\.Non\-invasive breast cancer. 3\.Inflammatory breast cancer. 4\.An existing serious, uncontrolled cardiac disease. 5\.Brain metastasis.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 4
A Pilot Study to Evaluate Efficacy and Safety of Fixed Dose Combination Capsules in Patients with GERD and Overlapping Symptoms of DyspepsiaHealth Condition 1: K219- Gastro-esophageal reflux disease without esophagitisCTRI/2020/09/027876Abbott India limited50
Active, not recruiting
Phase 1
Exploratory study of the efficacy and safety of flexible doses of Milnacipran and Venlafaxine administered in out patients with Major Depressive Disorder.EUCTR2006-003658-47-FRPierre Fabre Médicament - IRPF180
Completed
Phase 3
Evaluation of Efficacy and Safety of Combination of Atorvastatin and Hydroxychloroquine with Atorvastatin alone in Patients with DyslipidemiaHealth Condition 1: null- primary dyslipidemiaCTRI/2010/091/006138Ipca Laboratories Ltd Mumbai328
Completed
Not Applicable
Validation study of the efficacy and safety of first precutting for Oral protrusion-Large, which is difficult to biliary duct cannulation.Cases requiring ERCPJPRN-UMIN000042805Kitasato University School of Medicine38
Not yet recruiting
Phase 3
Comparative study of the efficacy and safety of FormoterolCTRI/2017/03/008277Rus Biopharm LLC136